Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 152 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Red Clear all

Conditions: Rosacea
Interventions: CD07805/47 Gel, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more

Conditions: Epidermis, Ultraviolet Exposure
Interventions: Hybrid sunscreen, Chemical sunscreen, No sunscreen; Drug · Other
Lead sponsor: Good Molecules, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Erythema
Interventions: MOB015B, MOB015B vehicle, Negative irritant solution of 0.9% saline; Drug
Lead sponsor: Moberg Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Erythematous (Type One) Rosacea
Interventions: V-101, vehicle; Drug · Other
Lead sponsor: Vicept Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 7
States / cities: San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more

Conditions: Erythema Nodosum Leprosum
Interventions: Dovramilast, Prednisolone, Thalidomide; Drug
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Rosacea
Interventions: Pulse Dye Laser/YAG laser; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Erythema, Edema
Interventions: Trojan "Simply Pleasure" Personal Lubricant; Device
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Skin Diseases, Keloid, Scar, Fibrosis, Hypertrophic Skin
Interventions: HF-LED-RL Phototherapy, Mock Therapy; Device
Lead sponsor: VA Northern California Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Mather, California

Conditions: Erythema, Maceration, Lesion Skin, Skin Folds
Interventions: DriGo Skin Protectant Textile; Device
Lead sponsor: Medline Industries; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa; Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 2 Months to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy, Clinically Significant Prostate Cancer, Transperineal
Interventions: MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy; Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Dry Eye, Eye Fatigue
Interventions: Eye Empower, Placebo; Dietary Supplement
Lead sponsor: Bio Nature Health; Industry
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Erythema, Inflammation
Interventions: Pomegranate Juice, Placebo Juice; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid
Interventions: topical infliximab; Drug
Lead sponsor: James Chodosh, MD, MPH; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rosacea
Interventions: Vehicle control, 2x/day, ACZONE (dapsone) Gel, 5%, 2x/day, ACZONE (dapsone) Gel, 5%, 1x/day, MetroGel® (metronidazole gel), 1.0% 1x/day, ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more

Conditions: Erythema, Edema
Interventions: Miami w/o frag Personal lubricant; Device
Lead sponsor: Church & Dwight Company, Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Piscataway, New Jersey

Conditions: Wrinkle, Skin Red
Interventions: 16 weeks mango intake; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Erythema
Interventions: Medical tapes: TegadermTM and EyeGard®; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma
Interventions: diagnostic imaging; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2050
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions: Abatacept; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Toxic Epidermal Necrolysis
Interventions: Isotretinoin, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 69 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sebum Production, Stool Microbiome, Transepidermal Water Loss, Facial Brrightness, Erythema, Wrinkles, Facial Shine
Interventions: Placebo Oral Tablet, Rubia Cordifolia, Triphala; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Acne Rosacea
Interventions: PRK 124; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Irvine, California

Search by objective public record fields.

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

Dose Response Study of Patients With Erythematous Rosacea

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

Effects of Phytonutrients on Vascular Health and Skin in Obese Males

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.

A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects

Influence of Mango Intake of Skin Health in Postmenopausal Women

Tegaderm vs. EyeGard for Eye Protection

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

Investigation of the Genetics of Hematologic Diseases

Bone Marrow Transplant With Abatacept for Non-Malignant Diseases

Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study

Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin

Effects of PRK 124 Lotion in Acne Rosacea